Randomized study to evaluate the efficacy and safety of AUR101 in patients with moderate-to-severe psoriasis.
8 visits in a 14 week stand.
Criteria:1. Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months
before screening
2. Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10
% at screening and Day 1
3. Static 5-point IGA modified [mod] 2011 scale of 3 or higher at screening and Day
1
4. Adult males or females, ≥ 18 to ≤ 70 years of age
5. Ability to communicate well with the investigator and to comply with the
requirements of the entire study
6. Willingness to give written informed consent (prior to any study related
procedures being performed) and ability to adhere to the study restrictions and
assessments schedule